



1652

Please type plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/025,514
Filing Date	December 18, 2001
First Named Inventor	Philip J. BARR
Group Art Unit	1652
Examiner Name	M. Walicka
Attorney Docket No.	368292000200

RECEIVED

APR 14 2003

TECH CENTER 1600/2900

Total Number Of Pages In This Submission

13 PAGES + 5
REFERENCES

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Copy of Invitation to Pay Additional Fees dated March 13, 2003 - 7 pages
<input checked="" type="checkbox"/> Information Disclosure Statement (Supplemental) - 3 pages	<input type="checkbox"/> Request for Refund	2. Form PTO-1449 + copy - 2 pages
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	3. Return receipt postcard
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		4. Five (5) references
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018
Signature	Eric Witt (Registration No. 44,408)
Date	April 4, 2003

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on April 4, 2003.

Julie M. Hassell

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT
Docket No. 368292000200

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on April 4, 2003.

Julie M. Hassell
Julie M. Hassell

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 14 2003

In the application of:

Philip J. BARR et al.

Serial No.: 10/025,514

Filing Date: December 18, 2001

For: MULTIFUNCTIONAL PROTEASE
INHIBITORS AND THEIR USE IN
TREATMENT OF DISEASE

Examiner: M. Walicka

Group Art Unit: 1652

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

06/20/2003 STARKEL 00000001 031352 10025514

00 F21636 160.00 BA

The documents listed on the attached Form PTO-1449 were cited in an Invitation to Pay Additional Fees dated March 13, 2003 (copy attached) directed to a counterpart international or foreign application and were not previously submitted in an Information Disclosure Statement.

This Supplemental Information Disclosure Statement is submitted:

- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☒ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.)

Certificate of Prompt Filing under 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been

made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 368292000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 4, 2003

Respectfully submitted,

By: 

Eric Witt
Registration No. 44,408

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5755
Facsimile: (650) 494-0792

Form PTO-1449

Docket Number 368292000200

Application Number 10/025,514

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Philip J. BARR et al.

Filing Date December 18, 2001

Group Art Unit 1652

Mailing Date April 4, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
----------------------	-------------	------	--------------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	09/28/1988	EP 0 283 932	Europe			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	2.	Barnes, P.J. (1999). "Novel Approaches and Targets for Treatment of Chronic Obstructive Pulmonary Disease," <i>American Journal of Respiratory and Critical Care Medicine</i> 160(5):S72-S79.
	3.	Lee, G.F. et al. (1997). "Potent Bifunctional Anticoagulants: Kunitz Domain—Tissue Factor Fusion Proteins," <i>Biochemistry</i> 36(19):5607-5611.
	4.	Schasteen, C.S. et al. (1991). "Synthetic Peptide Inhibitors of Complement Serine Proteases - III. Significant Increase In Inhibitor Potency Provides Further Support For The Functional Equivalence Hypothesis," <i>Molecular Immunology</i> 28(1/2):17-26.
	5.	Urwin, P.E. et al. (1998). "Enhanced Transgenic Plant Resistance to Nematodes by Dual Proteinase Inhibitor Constructs," <i>Planta</i> 204:472-479.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.